Document Detail


Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome.
MedLine Citation:
PMID:  15533640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is estimated that about 1 million patients are hospitalized for acute coronary events each years in the United States. An acceptable theory is that the acute coronary syndrome is caused by rupture of the atherosclerotic plaque with superimposed thrombus, which is a complex process and involving a number of different stages. Previous studies indicated that inflammation is one of the most important features of vulnerable plaque, and occurs in most vulnerable plaque, comprised of monocytes, macrophages, and lymphocytes in both the cap and in the adventitia. This is supported by evidence that reduction in serum inflammatory marker levels, such as C-reactive protein, significantly decreased coronary events in patients with acute coronary syndrome. A large number of investigations have demonstrated that administration of statin could modify C-reactive protein concentrations with a concurrent fall in cardiovascular events. Our recent data indicated that reduction of inflammatory markers could be achieved within 24 h following a single dose of statin administration after admission in patients with coronary artery disease. Based on the available evidence and in light of the new understanding that statins have pleiotropic effects, especially as a potent anti-inflammatory agent, the statins, like aspirin, should be clinically given as early as possible in patients with acute coronary syndrome.
Authors:
Chun-Hong Fang; Jian-Jun Li; Rui-Tai Hui
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Medical hypotheses     Volume:  64     ISSN:  0306-9877     ISO Abbreviation:  Med. Hypotheses     Publication Date:  2005  
Date Detail:
Created Date:  2004-11-09     Completed Date:  2005-04-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  192-6     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Renmin Hospital, Wuhan University School of Medicine, Wuhan 430060, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Anti-Inflammatory Agents / administration & dosage
Aspirin / administration & dosage*
C-Reactive Protein / immunology*
Clinical Trials as Topic
Coronary Disease / drug therapy*,  immunology*
Evidence-Based Medicine
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Models, Immunological*
Myocardial Infarction / drug therapy,  immunology
Risk Assessment / methods*
Risk Factors
Syndrome
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 50-78-2/Aspirin; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Abnormal proinsulin congeners as autoantigens that initiate the pathogenesis of Type 1 diabetes.
Next Document:  Adenosine A2a receptor/dopamine D2 receptor hetero-oligomerization: a hypothesis that may explain be...